Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

FDA OKs New Drug to Treat All Forms of Hepatitis C

By Linda A. Johnson, AP Medical Writer | August 4, 2017

U.S. regulators have approved another drug to treat all forms of hepatitis C that works in as little as eight weeks.

AbbVie’s drug, Mavyret, was approved Thursday by the Food and Drug Administration for patients without significant cirrhosis who haven’t been treated previously for the liver-destroying virus, plus those with a form of hepatitis who were not cured by a prior treatment.

Mavyret joins two other AbbVie hepatitis C drugs, one from Merck and several from Gilead on the market.

The list price without insurance will range from $26,400 for eight weeks’ treatment to $52,800 for 16 weeks’ treatment.

Hepatitis C affects at least 2.7 million people in U.S. The virus develops slowly over decades and many people don’t realize they are infected until signs of liver damage emerge.

(Source: Associated Press)

Related Articles Read More >

Glass vials moving through the filling station of a Flexicon liquid filling machine
How local regulations are becoming global pharma manufacturing standards 
AI in clinical trials: practical uses and limits
A photo of Fujifilm Biotechnologies' Holly Springs, North Carolina, facility.
Fujifilm Biotechnologies selected for FDA PreCheck Pilot Program
Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE